

Outlook Therapeutics, Inc. Logo

Outlook Therapeutics® to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

September 21, 2023

Live video webcast panel presentation on Tuesday, September 26th at 1:35 PM ET

ISELIN, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- [Outlook Therapeutics, Inc.](#) (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced that Russell Trenary, President and CEO of Outlook Therapeutics will participate in a panel presentation at the [2023 Cantor Fitzgerald Global Healthcare Conference](#) being held in New York, NY on Tuesday, September 26, 2023 at 1:35 PM ET.

In addition to the panel presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the [conference website](#).

A [live video webcast](#) of the panel presentation will be accessible on the [Events](#) page in the [Investors](#) section of the Company's website ([outlooktherapeutics.com](#)). A webcast replay will be archived for 90 days following the event.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company working to achieve FDA approval for the launch of ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. The FDA accepted Outlook Therapeutics' BLA submission for ONS-5010 to treat wet AMD with an initial PDUFA goal date of August 29, 2023; FDA did not approve the BLA during this review cycle and the Company is working with the FDA to address the issues that have been raised so that the BLA may be re-submitted. The submission is supported by Outlook Therapeutics' wet AMD clinical program, which consists of three clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan, and other markets. As part of the Company's multi-year commercial planning process, Outlook Therapeutics and Cencora, formerly AmerisourceBergen, entered into a strategic commercialization agreement to expand the Company's reach for connecting to retina specialists and their patients. Cencora will provide third-party logistics (3PL) services and distribution, as well as pharmacovigilance services and other services in the United States. For more information, please visit [www.outlooktherapeutics.com](#).

CONTACTS:

Media Inquiries:

Harriet Ullman
Vice President
LaVoieHealthScience
T: 617.429.5475
hullman@lavoiehealthscience.com

Investor Inquiries:

Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
OTLK@jtcir.com



Source: Outlook Therapeutics, Inc.